An enhanced anti-apoptotic capacity of tumor cells plays an important role in the process of breakpoint cluster region/Abelson tyrosine kinase gene (BCR/ABL)-independent imatinib resistance. We have previously demonstrated that brain expressed X-linked 1 (BEX1) was silenced in secondary imatinib-resistant K562 cells and that re-expression of BEX1 can restore imatinib sensitivity resulting in the induction of apoptosis. However, the mechanism by which BEX1 executes its pro-apoptotic function remains unknown. We identified B-cell lymphoma 2 (BCL-2) as a BEX1-interacting protein using a yeast two-hybrid screen. The interaction between BEX1 and BCL-2 was subsequently confirmed by co-immunoprecipitation assays. Like BCL-2, BEX1 was localized to the mitochondria. The region between 33K and 64Q on BEX1 is important for its localization to the mitochondria and its ability to interact with BCL-2. Additionally, we found that this region is essential for BEX1-regulated imatinib-induced apoptosis. Furthermore, we demonstrated that the interaction between BCL-2 and BEX1 promotes imatinib-induced apoptosis by suppressing the formation of anti-apoptotic BCL-2/BCL-2-associated X protein (BAX) heterodimers. Our results revealed an interaction between BEX1 and BCL-2 and a novel mechanism of imatinib resistance mediated by the BEX1/BCL-2 pathway.
References
[1]
Giuliani F, Colucci G (2012) Is there something other than imatinib mesilate in therapeutic options for GIST. Expert Opin Ther Targets 16 Suppl 2S35–43. doi: 10.1517/14728222.2012.657627
[2]
Ohanian M, Cortes J, Kantarjian H, Jabbour E (2012) Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 13: 927–938. doi: 10.1517/14656566.2012.672974
[3]
Lee F, Fandi A, Voi M (2008) Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 40: 334–343. doi: 10.1016/j.biocel.2007.10.001
[4]
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876–880. doi: 10.1126/science.1062538
[5]
Milojkovic D, Apperley J (2009) Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 15: 7519–7527. doi: 10.1158/1078-0432.ccr-09-1068
[6]
Karvela M, Helgason GV, Holyoake TL (2012) Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Rev Anticancer Ther 12: 381–392. doi: 10.1586/era.12.10
[7]
Juan WC, Ong ST (2012) The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia. Prog Mol Biol Transl Sci 106: 107–142. doi: 10.1016/b978-0-12-396456-4.00007-9
[8]
Burchert A, Wang Y, Cai D, von BN, Paschka P, et al. (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774–1782. doi: 10.1038/sj.leu.2403898
[9]
Wang Y, Cai D, Brendel C, Barett C, Erben P, et al. (2007) Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109: 2147–2155. doi: 10.1182/blood-2006-08-040022
[10]
Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, et al. (2006) Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A 103: 7444–7449. doi: 10.1073/pnas.0602402103
[11]
Schmitt CA, Rosenthal CT, Lowe SW (2000) Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6: 1029–1035. doi: 10.1038/79542
[12]
Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633–2643. doi: 10.1172/jci117965
[13]
Niture SK, Jaiswal AK (2012) Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem 287: 9873–9886. doi: 10.1074/jbc.m111.312694
[14]
Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, et al. (2004) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 24: 6172–6183. doi: 10.1128/mcb.24.14.6172-6183.2004
[15]
Gordon PM, Fisher DE (2010) Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line. J Biol Chem 285: 14109–14114. doi: 10.1074/jbc.m109.078592
[16]
Ding K, Su Y, Pang L, Lu Q, Wang Z, et al. (2009) Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+ leukemic cells. Carcinogenesis 30: 35–42. doi: 10.1093/carcin/bgn251
[17]
Yang QS, Xia F, Gu SH, Yuan HL, Chen JZ, et al. (2002) Cloning and expression pattern of a spermatogenesis-related gene, BEX1, mapped to chromosome Xq22. Biochem Genet 40: 1–12.
[18]
Alvarez E, Zhou W, Witta SE, Freed CR (2005) Characterization of the Bex gene family in humans, mice, and rats. Gene 357: 18–28. doi: 10.1016/j.gene.2005.05.012
[19]
Foltz G, Ryu GY, Yoon JG, Nelson T, Fahey J, et al. (2006) Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res 66: 6665–6674. doi: 10.1158/0008-5472.can-05-4453
[20]
Naderi A, Liu J, Hughes-Davies L (2010) BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer. Mol Cancer 9: 111. doi: 10.1186/1476-4598-9-111
[21]
Behrens M, Margolis JW, Margolis FL (2003) Identification of members of the Bex gene family as olfactory marker protein (OMP) binding partners. J Neurochem 86: 1289–1296. doi: 10.1046/j.1471-4159.2003.01940.x
[22]
Thomadaki H, Scorilas A (2006) BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 43: 1–67. doi: 10.1080/10408360500295626
[23]
Pratesi G, Perego P, Zunino F (2001) Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. Biochem Pharmacol 61: 381–386. doi: 10.1016/s0006-2952(00)00538-4
[24]
Ku B, Liang C, Jung JU, Oh BH (2011) Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res 21: 627–641. doi: 10.1038/cr.2010.149
[25]
Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609–619. doi: 10.1016/0092-8674(93)90509-o
[26]
Naderi A, Teschendorff AE, Beigel J, Cariati M, Ellis IO, et al. (2007) BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res 67: 6725–6736. doi: 10.1158/0008-5472.can-06-4394
[27]
Naderi A, Liu J, Bennett IC (2010) BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. Int J Cancer 126: 1596–1610. doi: 10.1002/ijc.24866
[28]
Kelly PN, Strasser A (2011) The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 18: 1414–1424. doi: 10.1038/cdd.2011.17
[29]
Dai Y, Rahmani M, Corey SJ, Dent P, Grant S (2004) A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279: 34227–34239. doi: 10.1074/jbc.m402290200
[30]
Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, et al. (1998) Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 273: 30777–30784. doi: 10.1074/jbc.273.46.30777
[31]
Melarangi T, Zhuang J, Lin K, Rockliffe N, Bosanquet AG, et al. (2012) Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. Cell Death Dis 3: e372. doi: 10.1038/cddis.2012.102
[32]
Burke SP, Smith L, Smith JB (2010) cIAP1 cooperatively inhibits procaspase-3 activation by the caspase-9 apoptosome. J Biol Chem 285: 30061–30068. doi: 10.1074/jbc.m110.125955
